Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. The drug was given by intravenous infusion at a dose of 700 mg/m2 every 21 days. There were no objective responses. Grades III and IV toxic effects were limited to granulocytopenia in 42% of courses and anemia in 5% of courses. There was one case of grade III increase in transaminases. Our results show that at this dose and schedule, CI-958 lacks activity against colorectal cancer.

Full Text

Duke Authors

Cited Authors

  • Hoff, PM; Ellerton, JA; Dakhil, SR; Winn, RJ; Abbruzzese, JL; Pazdur, R

Published Date

  • December 2000

Published In

Volume / Issue

  • 23 / 6

Start / End Page

  • 602 - 604

PubMed ID

  • 11202806

International Standard Serial Number (ISSN)

  • 0277-3732

Digital Object Identifier (DOI)

  • 10.1097/00000421-200012000-00015


  • eng

Conference Location

  • United States